Headquartered in California but havig facailites in Ireland and twolocationin China., DiaCarta is a translational genomics and personalized diagnostics company organized around the provision of highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. DiaCarta scientists have developed innovative new nucleic acid molecular oligomers that hybridize by Watson-Crick base pairing to target DNA sequences yet have a modified chemical backbone. The xenonucleic acid oligomers are highly effective at hybridizing to target sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (PCR) or as highly specific molecular probes for detection of nucleic acid target sequences. DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix.The precise molecular diagnostic cancer assays offered by DiaCarta enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.
